Parameter
| Biomarker | Gly、Pro、Gln、Glu | Full name | glycine, proline, glutamine/glutamate | Molecular Type | Metabolite |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | diagnosis, prognosis, therapeutic targets | ||
| Disease | Multiple Myeloma (MM) | Disease Subtypes | / | ||
| Organ | Bone marrow, Serum | Test Sample / Technology Platform | serum、marrow | ||
| Pathobiological Mechanisms | Glycine disrupts glutathione balance and promotes proliferation; Proline originates from collagen degradation and is associated with osteolytic lesions; Glutamine metabolism provides energy. | ||||
| Clinical Availability Status | Research validation/early clinical | ||||
| Notes and Dynamics | Glycine inhibitors enhance bortezomib sensitivity; Proline dehydrogenase (PRODH) downregulation is associated with drug resistance; Glutamine transporter LAT1 inhibitors show preclinical efficacy | ||||